ClinicalTrials.gg
CompletedNCT00939003Updated Sep 9, 2014Results posted

Study of Adalimumab in Patients With Axial Spondyloarthritis

A Phase 3 interventional study of Adalimumab and Placebo in Axial Spondyloarthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 38 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-09.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.

Enrollment
17th of 31
192 · median 200
Started
2009
the only one that year
Phase 3
13 of 34
none open now
Registered
1st of 34
by date

Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one is the 17th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2009, is one of 13 in phase 3, and was the 1st registered.

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Axial Spondyloarthritis with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate how well adalimumab works in the short and long term in patients with axial spondyloarthritis who are not diagnosed as having either ankylosing spondylitis or psoriatic arthritis.

Read the detailed description

This is a Phase 3, placebo-controlled, double-blind randomized study with an open-label phase designed to evaluate the efficacy and safety of adalimumab 40 mg administered every other week in adult patients with active axial spondyloarthritis (SpA) who are not diagnosed with ankylosing spondylitis, psoriasis, or psoriatic arthritis and who have had an inadequate response or intolerance to one or more nonsteroidal anti-inflammatory drugs (NSAIDs) or had a contraindication to NSAIDs. Participants receive adalimumab or placebo for 12 weeks during the double-blind phase of the study. Following the double-blind phase, all remaining participants enter the open-label phase of the study in which they receive open-label adalimumab for up to 144 weeks. Efficacy endpoints include the Assessment of Spondyloarthritis International Society (ASAS) response criteria for patients with SpA. These response criteria were used to determine participants who were responders. ASAS response involves evaluations in the following 4 domains: participant's global assessment of disease activity, pain, function, and inflammation. The patient's global assessment of disease activity score is assessed using a 100 millimeter (mm) visual analog scale (VAS; 0 for no disease activity to 100 for severe disease activity). Pain is represented as a total back pain score and is assessed using a 100 mm VAS (0 for no pain to 100 for most severe pain). Function score is represented as the Bath Ankylosing Spondylitis (AS) Functional Index (BASFI) 100 mm VAS score (average of the ability to perform 10 activities, each scored as 0 for easy to 100 for impossible). Inflammation is determined using the morning stiffness overall level score (0 for none to 10 for very severe) and duration score (0 for 0 hours to 10 for ≥ 2 hours) of the Bath AS Disease Activity Index (BASDAI) (mean of these items #5 and #6 scores). In addition, the BASDAI is used as an efficacy endpoint. The BASDAI is used by the participant to assess his/her disease activity. Using VAS scales, the participant answers 6 questions pertaining to symptoms experienced over the past week. For 5 questions (levels of: fatigue/tiredness; AS neck, back, or hip pain; pain/swelling; discomfort at areas tender to touch or pressure; and morning stiffness), the response scale is 0 (none) to 10 (very severe). For 1 question (duration of morning stiffness), the response scale is 0 (0 hours) to 10 (≥ 2 or more hours).

03

Conditions studied

  • Axial Spondyloarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with inadequate response to >/= 1 non-steroidal anti-inflammatory drugs (NSAIDs)
  • Chronic back pain with onset \< 45 years of age
  • Magnetic resonance imaging (MRI) indicating active sacroiliitis or positive human leukocyte antigen-B27 (HLA-B27) blood test in addition to meeting spondyloarthritis clinical criteria
  • Negative purified protein derivative (PPD) test and chest x-ray performed at Baseline visit must be negative
  • Ability to administer subcutaneous injections
  • General good health otherwise

Exclusion criteria

Exclusion Criteria:

  • Prior anti-tumor necrosis factor (TNF) therapy
  • Psoriasis or psoriatic arthritis
  • Fulfillment of modified New York criteria for ankylosing spondylitis
  • Recent infection requiring treatment
  • Significant medical events or conditions that may put patients at risk for participation
  • Females who are pregnant or breast-feeding or considering becoming pregnant during the study
  • History of cancer, except successfully treated skin cancer
  • Recent history of drug or alcohol abuse
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Biological: Adalimumab

  • Placebo comparator
    Placebo

    Biological: Placebo

  • Experimental
    Open-label Adalimumab

    Biological: Open-label Adalimumab

Interventions

  • BiologicalAdalimumab

    40 mg every other week up to Week 12

    Also known as: ABT-D2E7, Humira

  • BiologicalPlacebo

    Placebo every other week up to Week 12

  • 40 mg every other week, Week 12 through Week 156

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response

    ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 20 units (on a scale from 0 to 100) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units on a scale from 0 to 100) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response

    ASAS20 response was defined as improvement of ≥ 20% relative to Baseline and absolute improvement of ≥ 10 units (on a scale from 0 to 100) in ≥ 3 of the following 4 domains with no deterioration (defined as a change for the worse of ≥ 20% and net worsening of ≥ 10 units) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Week 12

  2. Number of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response

    The Bath Ankylosing Spondylitis (AS) Disease Activity Index assesses disease activity by asking the participant to answer 6 questions (each on a 10 cm VAS) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 cm. Lower scores indicate less disease activity. BASDAI50 is a 50% improvement from Baseline in BASDAI score.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Short Form-36 (SF-36) Physical Component Summary Score

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life. The SF-36 consists of 36 questions in 8 domains (limitations in physical functioning due to health problems; limitations in usual role because of physical health problems; bodily pain; general health perceptions; vitality; limitations in social functioning because of physical or emotional problems; limitations in usual role due to emotional problems; and general mental health). Two component scores can be summarized: physical and mental; domains 1-4 comprise the physical component summary of the SF-36. A transformed summary score is calculated ranging from 0 to 100 where higher scores indicate a higher level of functioning. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 12

  4. Number of Participants Achieving ASAS Partial Remission

    ASAS partial remission is an absolute score of \< 20 units on a 0 to 100 scale for each of the four following domains: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Week 12

  5. Number of Participants Achieving an ASAS5/6 Response

    ASAS5/6 response is a 20% improvement in five out of the following six domains: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none) to 10 (very severe/2 hours or more duration). * Spinal mobility, measured from the lateral lumbar flexion score of the Bath AS Metrology Index (BASMI) on a scale from 0 (best mobility) to 10 (worst mobility); * C-reactive protein level (lower levels indicate less inflammation).

    Time frame: Baseline and Week 12

  6. Change From Baseline in Disability Index of Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S)

    Health Assessment Questionnaire modified for spondyloarthropathies (HAQ-S) is a self-reported measure to assess the physical function and health-related quality of life. The Disability Index (DI) of HAQ-S is calculated as the mean of the following 8 category scores (range: 0 \[without any difficulty\] to 3 \[unable to do\]): Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Five additional items in the functional status measure were included in the HAQ-S, including carrying heavy packages, sitting for long periods, able to work at a flat topped table, and (if the participant had a driver's license or a car) able to look in the rear view mirror and able to turn head to drive in reverse. The overall score ranges from 0 (no disability) to 3 (three very severe, high-dependency disability). Negative mean changes from Baseline in the overall score indicate improvement.

    Time frame: Baseline and Week 12

  7. Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)

    C-reactive protein (CRP) is considered an efficacy variable for the axial spondyloarthritis indication. It is a general marker of inflammation that is sensitive to acute changes in inflammatory response. Higher levels indicate more inflammation.

    Time frame: Baseline and Week 12

  8. Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for Sacroiliac Joints

    Six consecutive sacroiliac (SI) joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema using SPARCC scoring. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema; the maximum score is 8 per slice and maximum score for 6 SI joint slices is 48. Intensity of edema: A score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice. The maximum score is 2 per slice and 12 for 6 slices. A lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The maximum score per slice is 2 and for 6 slices 12. The total maximum score for all SI joints across 6 slices is 72.

    Time frame: Baseline and Week 12

  9. Change From Baseline in SPARCC MRI Score for the Spine

    Six discovertebral units (DVU) representing the 6 most abnormal DVUs, and 3 consecutive sagittal slices at each DVU representing the most abnormal slices for that DVU were selected for scoring. Each DVU was divided into 4 quadrants and scored for the presence (1) or absence (0) of edema. The maximum score is 12 per DVU. The maximum score is 72 for 6 DVUs. If edema was present in at least 1 quadrant of a DVU slice, it was scored for intensity and depth of the edema representing that slice: A score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. The maximum score for intensity per slice is 1, per DVU is 3 and for 6 DVUs is 18. A lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the surface of the endplate in any quadrant. The maximum score per slice is 1, for a DVU is 3 and for 6 DVUs is 18. The total maximum SPARCC score for all 6 DVUs is 108.

    Time frame: Baseline and Week 12

Other outcomes

  1. Number of Participants Reporting Adverse Events

    Adverse events were collected at designated study visits for all participants who received at least 1 dose of study drug. The number of participants experiencing any adverse event (serious and non-serious) is summarized.

    Time frame: Through Week 12

  2. Number of Participants With Blood Hematology or Chemistry Values Common Toxicity Criteria Grade ≥ 3

    Blood was collected for analysis at designated study visits; hematology and chemistry results were provided by a central laboratory. The number of participants with an abnormal laboratory result (higher then upper normal limit or lower than lower normal limit) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized.

    Time frame: Through Week 12

  3. Number of Participants Achieving an ASAS20 Response During the Open-label Period

    ASAS20 response was defined as improvement of ≥ 20% relative to Baseline and absolute improvement of ≥ 10 units (on a scale from 0 to 100) in ≥ 3 of the following 4 domains with no deterioration (defined as a change for the worse of ≥ 20% and net worsening of ≥ 10 units) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Weeks 52, 104, and 156

  4. Number of Participants Achieving an ASAS40 Response During the Open-label Period

    ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 20 units (on a scale from 0 to 100) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units on a scale of 0 to 100) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Weeks 52, 104, and 156

  5. Number of Participants Achieving a BASDAI50 Response During the Open-label Period

    The Bath Ankylosing Spondylitis (AS) Disease Activity Index assesses disease activity by asking the participant to answer 6 questions (each on a 10 cm VAS) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 cm. Lower scores indicate less disease activity. BASDAI50 is a 50% improvement from Baseline in BASDAI score.

    Time frame: Baseline and Weeks 52, 104, and 156

07

Results

Posted Mar 6, 2012

Participant flow

Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestonePlaceboAdalimumab
Started9795
Completed9591
Not completed24
Withdrew: Adverse event11
Withdrew: Lack of efficacy01
Withdrew: Pregnancy01
Withdrew: Mri not diagnostic11
Open-label Treatment Period
Participant flow — Open-label Treatment Period
MilestonePlaceboAdalimumab
Started9591
Completed6662
Not completed2929
Withdrew: Adverse event48
Withdrew: Withdrawal by subject147
Withdrew: Lack of efficacy69
Withdrew: Pregnancy11
Withdrew: Exclusion criteria10
Withdrew: Site closure34

Outcome measures

PrimaryNumber of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response

ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 20 units (on a scale from 0 to 100) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units on a scale from 0 to 100) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Week 12
Reported as:
Number · participants
Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response
participantsDouble-blind PlaceboDouble-blind Adalimumab
Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response1433
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · Chi-squared · p = <0.001
SecondaryNumber of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response

ASAS20 response was defined as improvement of ≥ 20% relative to Baseline and absolute improvement of ≥ 10 units (on a scale from 0 to 100) in ≥ 3 of the following 4 domains with no deterioration (defined as a change for the worse of ≥ 20% and net worsening of ≥ 10 units) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Week 12
Reported as:
Number · participants
Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response
participantsDouble-blind PlaceboDouble-blind Adalimumab
Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response2947
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · Chi-squared · p = 0.004
SecondaryNumber of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response

The Bath Ankylosing Spondylitis (AS) Disease Activity Index assesses disease activity by asking the participant to answer 6 questions (each on a 10 cm VAS) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 cm. Lower scores indicate less disease activity. BASDAI50 is a 50% improvement from Baseline in BASDAI score.

Time frame:
Baseline and Week 12
Reported as:
Number · participants
Number of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response
participantsDouble-blind PlaceboDouble-blind Adalimumab
Number of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response1432
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · Chi-squared · p = 0.001
SecondaryChange From Baseline in Short Form-36 (SF-36) Physical Component Summary Score

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life. The SF-36 consists of 36 questions in 8 domains (limitations in physical functioning due to health problems; limitations in usual role because of physical health problems; bodily pain; general health perceptions; vitality; limitations in social functioning because of physical or emotional problems; limitations in usual role due to emotional problems; and general mental health). Two component scores can be summarized: physical and mental; domains 1-4 comprise the physical component summary of the SF-36. A transformed summary score is calculated ranging from 0 to 100 where higher scores indicate a higher level of functioning. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Short Form-36 (SF-36) Physical Component Summary Score
units on a scaleDouble-blind PlaceboDouble-blind Adalimumab
Change From Baseline in Short Form-36 (SF-36) Physical Component Summary Score2.0 ± 7.045.5 ± 8.98
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · ANCOVA · p = 0.001ANCOVA model adjusting for Baseline value with treatment as a factor.
SecondaryNumber of Participants Achieving ASAS Partial Remission

ASAS partial remission is an absolute score of \< 20 units on a 0 to 100 scale for each of the four following domains: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants Achieving ASAS Partial Remission
participantsDouble-blind PlaceboDouble-blind Adalimumab
Number of Participants Achieving ASAS Partial Remission515
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · Chi-squared · p = 0.014
Other pre-specifiedNumber of Participants Reporting Adverse Events

Adverse events were collected at designated study visits for all participants who received at least 1 dose of study drug. The number of participants experiencing any adverse event (serious and non-serious) is summarized.

Time frame:
Through Week 12
Reported as:
Number · participants
Number of Participants Reporting Adverse Events
participantsDouble-blind PlaceboDouble-blind Adalimumab
Number of Participants Reporting Adverse Events5755
Other pre-specifiedNumber of Participants With Blood Hematology or Chemistry Values Common Toxicity Criteria Grade ≥ 3

Blood was collected for analysis at designated study visits; hematology and chemistry results were provided by a central laboratory. The number of participants with an abnormal laboratory result (higher then upper normal limit or lower than lower normal limit) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized.

Time frame:
Through Week 12
Reported as:
Number · participants
Number of Participants With Blood Hematology or Chemistry Values Common Toxicity Criteria Grade ≥ 3
participantsDouble-blind PlaceboDouble-blind Adalimumab
Number of Participants With Blood Hematology or Chemistry Values Common Toxicity Criteria Grade ≥ 364
SecondaryNumber of Participants Achieving an ASAS5/6 Response

ASAS5/6 response is a 20% improvement in five out of the following six domains: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none) to 10 (very severe/2 hours or more duration). * Spinal mobility, measured from the lateral lumbar flexion score of the Bath AS Metrology Index (BASMI) on a scale from 0 (best mobility) to 10 (worst mobility); * C-reactive protein level (lower levels indicate less inflammation).

Time frame:
Baseline and Week 12
Reported as:
Number · participants
Number of Participants Achieving an ASAS5/6 Response
participantsDouble-blind PlaceboDouble-blind Adalimumab
Number of Participants Achieving an ASAS5/6 Response628
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · Chi-squared · p = <0.001
SecondaryChange From Baseline in Disability Index of Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S)

Health Assessment Questionnaire modified for spondyloarthropathies (HAQ-S) is a self-reported measure to assess the physical function and health-related quality of life. The Disability Index (DI) of HAQ-S is calculated as the mean of the following 8 category scores (range: 0 \[without any difficulty\] to 3 \[unable to do\]): Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Five additional items in the functional status measure were included in the HAQ-S, including carrying heavy packages, sitting for long periods, able to work at a flat topped table, and (if the participant had a driver's license or a car) able to look in the rear view mirror and able to turn head to drive in reverse. The overall score ranges from 0 (no disability) to 3 (three very severe, high-dependency disability). Negative mean changes from Baseline in the overall score indicate improvement.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Disability Index of Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S)
units on a scaleDouble-blind PlaceboDouble-blind Adalimumab
Change From Baseline in Disability Index of Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S)-0.1 ± 0.42-0.3 ± 0.49
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · ANCOVA · p = 0.027ANCOVA model adjusting for Baseline value with treatment as a factor.
SecondaryChange From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)

C-reactive protein (CRP) is considered an efficacy variable for the axial spondyloarthritis indication. It is a general marker of inflammation that is sensitive to acute changes in inflammatory response. Higher levels indicate more inflammation.

Time frame:
Baseline and Week 12
Reported as:
Mean · mg/L
Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
mg/LDouble-blind PlaceboDouble-blind Adalimumab
Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)-0.3 ± 6.39-4.7 ± 12.32
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · ANCOVA · p = <0.001ANCOVA model adjusting for Baseline value with treatment as a factor.
SecondaryChange From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for Sacroiliac Joints

Six consecutive sacroiliac (SI) joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema using SPARCC scoring. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema; the maximum score is 8 per slice and maximum score for 6 SI joint slices is 48. Intensity of edema: A score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice. The maximum score is 2 per slice and 12 for 6 slices. A lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The maximum score per slice is 2 and for 6 slices 12. The total maximum score for all SI joints across 6 slices is 72.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for Sacroiliac Joints
units on a scaleDouble-blind PlaceboDouble-blind Adalimumab
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for Sacroiliac Joints-0.6 ± 6.19-3.2 ± 8.34
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · ANCOVA · p = 0.003ANCOVA model adjusting for Baseline value with treatment as a factor.
SecondaryChange From Baseline in SPARCC MRI Score for the Spine

Six discovertebral units (DVU) representing the 6 most abnormal DVUs, and 3 consecutive sagittal slices at each DVU representing the most abnormal slices for that DVU were selected for scoring. Each DVU was divided into 4 quadrants and scored for the presence (1) or absence (0) of edema. The maximum score is 12 per DVU. The maximum score is 72 for 6 DVUs. If edema was present in at least 1 quadrant of a DVU slice, it was scored for intensity and depth of the edema representing that slice: A score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. The maximum score for intensity per slice is 1, per DVU is 3 and for 6 DVUs is 18. A lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the surface of the endplate in any quadrant. The maximum score per slice is 1, for a DVU is 3 and for 6 DVUs is 18. The total maximum SPARCC score for all 6 DVUs is 108.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in SPARCC MRI Score for the Spine
units on a scaleDouble-blind PlaceboDouble-blind Adalimumab
Change From Baseline in SPARCC MRI Score for the Spine-0.2 ± 3.35-1.8 ± 4.51
Statistical analysis
  • Double-blind Placebo vs Double-blind Adalimumab · ANCOVA · p = 0.001ANCOVA model adjusting for Baseline value with treatment as a factor.
Other pre-specifiedNumber of Participants Achieving an ASAS20 Response During the Open-label Period

ASAS20 response was defined as improvement of ≥ 20% relative to Baseline and absolute improvement of ≥ 10 units (on a scale from 0 to 100) in ≥ 3 of the following 4 domains with no deterioration (defined as a change for the worse of ≥ 20% and net worsening of ≥ 10 units) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Weeks 52, 104, and 156
Reported as:
Number · participants
Number of Participants Achieving an ASAS20 Response During the Open-label Period
participantsPlaceboAdalimumab
Week 52 (N=78, 72)5957
Week 104 (N=74, 64)5953
Week 156 (N=64, 58)5348
Other pre-specifiedNumber of Participants Achieving an ASAS40 Response During the Open-label Period

ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 20 units (on a scale from 0 to 100) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units on a scale of 0 to 100) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on a VAS ranging from 0 (easy) to 100 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) VAS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Weeks 52, 104, and 156
Reported as:
Number · participants
Number of Participants Achieving an ASAS40 Response During the Open-label Period
participantsPlaceboAdalimumab
Week 52 (N=78, 72)5042
Week 104 (N=74, 64)5138
Week 156 (N=64, 58)4437
Other pre-specifiedNumber of Participants Achieving a BASDAI50 Response During the Open-label Period

The Bath Ankylosing Spondylitis (AS) Disease Activity Index assesses disease activity by asking the participant to answer 6 questions (each on a 10 cm VAS) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 cm. Lower scores indicate less disease activity. BASDAI50 is a 50% improvement from Baseline in BASDAI score.

Time frame:
Baseline and Weeks 52, 104, and 156
Reported as:
Number · participants
Number of Participants Achieving a BASDAI50 Response During the Open-label Period
participantsPlaceboAdalimumab
Week 52 (N=78, 72)5242
Week 104 (N=74, 64)5040
Week 156 (N=64, 58)4639

Adverse events

Collected over Twelve weeks during the double blind period and up to Week 156 during the open-label period.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Placebo—1/97 (1%)32/97 (33%)
Double-blind Adalimumab—3/95 (3.2%)42/95 (44.2%)
Any Adalimumab—33/190 (17.4%)152/190 (80%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventDouble-blind PlaceboDouble-blind AdalimumabAny Adalimumab
HEPATITIS ACUTEHepatobiliary disorders0/971/951/190
CELLULITISInfections and infestations0/970/952/190
HEADACHENervous system disorders0/970/952/190
BREAST DYSPLASIAReproductive system and breast disorders0/971/951/190
ABORTION INDUCEDSurgical and medical procedures0/971/951/190
NAUSEAGastrointestinal disorders1/970/950/190
VOMITINGGastrointestinal disorders1/970/950/190
CHILLSGeneral disorders1/970/950/190
PYREXIAGeneral disorders1/970/950/190
DIZZINESSNervous system disorders1/970/950/190
Most frequent other events
Showing 10 of 47
Most frequent other events
EventDouble-blind PlaceboDouble-blind AdalimumabAny Adalimumab
NASOPHARYNGITISInfections and infestations3/9711/9552/190
SPONDYLITISMusculoskeletal and connective tissue disorders2/972/9537/190
BRONCHITISInfections and infestations2/971/9531/190
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations4/973/9519/190
HEADACHENervous system disorders3/976/9519/190
DIARRHOEAGastrointestinal disorders7/974/9518/190
SINUSITISInfections and infestations2/971/9518/190
PHARYNGITISInfections and infestations0/973/9515/190
NAUSEAGastrointestinal disorders7/977/9513/190
FATIGUEGeneral disorders0/973/9514/190

Baseline characteristics

Full analysis set, defined as all participants who received at least one dose of blinded study drug excluding seven participants from one site due to investigator non-compliance.

Age, Continuous
Age, Continuous(years)PlaceboDouble-blind AdalimumabTotal
Mean38.4 ± 10.3937.6 ± 11.2938.0 ± 10.82
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDouble-blind AdalimumabTotal
Female5447101
Male404484
08

Study locations

38 sites
  • Site Reference ID/Investigator# 21250
    Birmingham, Alabama 35205, United States
  • Site Reference ID/Investigator# 21249
    Colorado Springs, Colorado 80910, United States
  • Site Reference ID/Investigator# 21245
    Denver, Colorado 80230, United States
  • Site Reference ID/Investigator# 21246
    Wheaton, Maryland 20902, United States
  • Site Reference ID/Investigator# 26582
    Duncansville, Pennsylvania 16635, United States
  • Site Reference ID/Investigator# 21241
    Wyomissing, Pennsylvania 19610, United States
  • Site Reference ID/Investigator# 21243
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 21248
    Houston, Texas 77030, United States
  • Site Reference ID/Investigator# 21247
    Seattle, Washington 98122, United States
  • Site Reference ID/Investigator# 22342
    Brisbane, 4102, Australia
  • Site Reference ID/Investigator# 21223
    Kogarah, 2217, Australia
  • Site Reference ID/Investigator# 21222
    Maroochydore, 4558, Australia
  • Site Reference ID/Investigator# 21225
    Genk, 3600, Belgium
  • Site Reference ID/Investigator# 21224
    Ghent, 9000, Belgium
  • Site Reference ID/Investigator# 26544
    Gilly, 6060, Belgium
  • Site Reference ID/Investigator# 27382
    Merksem, 2170, Belgium
  • Site Reference ID/Investigator# 21229
    Edmonton, T6G 2S2, Canada
  • Site Reference ID/Investigator# 21226
    Sainte-Foy, Quebec, G1W 4R4, Canada
  • Site Reference ID/Investigator# 21227
    St. John's, A1C 5B8, Canada
  • Site Reference ID/Investigator# 21228
    Toronto, M5T 2S8, Canada
  • Site Reference ID/Investigator# 21231
    Brno, 65691, Czech Republic
  • Site Reference ID/Investigator# 26882
    Pardubice, 530 02, Czech Republic
  • Site Reference ID/Investigator# 21230
    Prague 2, 128 50, Czech Republic
  • Site Reference ID/Investigator# 26883
    Uherske Hradiste, 686 01, Czech Republic
  • Site Reference ID/Investigator# 21263
    Boulogne Billancourt, 92100, France
  • Site Reference ID/Investigator# 21262
    Chambray-les-Tour, 37170, France
  • Site Reference ID/Investigator# 21261
    Orleans, 45067, France
  • Site Reference ID/Investigator# 22343
    Paris Cedex 14, 75679, France
  • Site Reference ID/Investigator# 21266
    Berlin, 12200, Germany
  • Site Reference ID/Investigator# 21267
    Erlangen, 91054, Germany
  • Site Reference ID/Investigator# 21264
    Herne, 44652, Germany
  • Site Reference ID/Investigator# 21265
    Munich, 80336, Germany
  • Site Reference ID/Investigator# 21285
    Amsterdam, 1105 AZ, Netherlands
  • Site Reference ID/Investigator# 21284
    Leiden, 2333 ZA, Netherlands
  • Site Reference ID/Investigator# 21282
    A Coruna, 15006, Spain
  • Site Reference ID/Investigator# 21283
    Barcelona, 08907, Spain
  • Site Reference ID/Investigator# 21281
    Cordoba, 14004, Spain
  • Site Reference ID/Investigator# 21289
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • van der Heijde D, Sieper J, Maksymowych WP, Lambert RG, Chen S, Hojnik M, Anderson JK, Pangan AL. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial. Arthritis Res Ther. 2018 Mar 27;20(1):61. doi: 10.1186/s13075-018-1556-5. PubMed 29587851 ↗
  • van der Heijde D, Sieper J, Maksymowych WP, Brown MA, Lambert RG, Rathmann SS, Pangan AL. Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2014 Mar;66(3):667-73. doi: 10.1002/art.38283. PubMed 24574227 ↗
  • Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013 Jun;72(6):815-22. doi: 10.1136/annrheumdis-2012-201766. Epub 2012 Jul 7. PubMed 22772328 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Feb 2011 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2009
First posted
Jul 14, 2009
Start
Jul 2009
Primary completionActual
Feb 2011
CompletionActual
Aug 2013
Results first posted
Mar 6, 2012
Last update
Sep 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00939003
Responsible party
Sponsor
First posted
Jul 14, 2009
Start date
Jul 2009
Primary completion
Feb 2011
Completion
Aug 2013
Results posted
Mar 6, 2012
Last update
Sep 9, 2014

Study contacts

Aileen L Pangan, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion